Bristol-Myers Squibb Co. (BMY) News Nov 18, 2014, 4:20

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 9:50 PM

Bristol-Myers Squibb Co. (BMY) News Nov 18, 2014, 4:20 p.m.
MarketWatch News on BMY
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:05 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 11:31 a.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 9:49 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 6:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 6:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 sales $3.92 bln vs. $4.07 bln a year ago 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 adj. EPS 45 cents vs. FactSet consensus 42 cents 6:32 a.m. Oct. 24, 2014 - Tomi Kilgore
Mead Johnson Nutrition profit rises 9.5% 7:21 a.m. Oct. 23, 2014 - MarketWatch.com
More than 1/3 of Dow stocks to report this week 4:31 a.m. Oct. 19, 2014 - Wallace Witkowski
Bristol-Myers drops Hepatitis C dual regimen in U.S. 10:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
FDA approves Merck's new-kind of cancer drug 1:58 p.m. Sept. 4, 2014 - MarketWatch.com
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Glaxo chief faces increasing pressure: WSJ 5:29 p.m. Aug. 11, 2014 - MarketWatch.com
Bristol-Myers adjusted profit beats expectations 7:24 a.m. July 24, 2014 - MarketWatch.com
Mead Johnson sales rise, raises outlook 7:04 a.m. July 22, 2014 - MarketWatch.com
Loading more headlines...
Advertisement
Other News on BMY
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Today - Seeking Alpha
India Divided on Whether to Break Bristol-Myers Drug Patent 4:48 a.m. Today - The Wall Street Journal Interactive Edition
Yearly Dividend Hikes Aren't Always Necessary In A Successful Dividend Growth Portfolio 4:41 p.m. Nov. 17, 2014 - Seeking Alpha
Incyte Building Blockbuster Drug One Disease At A Time 2:58 p.m. Nov. 17, 2014 - Investors Business Daily
Adexanet Alfa reverses anticoagulant effect of Eliquis in first stage of Phase 3 9:57 a.m. Nov. 17, 2014 - Seeking Alpha
Dividend Challengers (And Near-Challengers): 44 Increase Expected By January 31 4:57 a.m. Nov. 17, 2014 - Seeking Alpha
FDA reviewing long-term death risk of antiplatelet therapies 5:08 p.m. Nov. 16, 2014 - Seeking Alpha
Anticlotting Push Urged for Heart Patients With Stents 5:01 p.m. Nov. 16, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers Drug Shows Promise for Skin-Cancer Patients 3:45 a.m. Nov. 16, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers Plans Ireland Plant 6:30 a.m. Nov. 14, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
Ad Comm meeting approaches to discuss risks of epidural steroid injections 11:56 a.m. Nov. 13, 2014 - Seeking Alpha
Analysts' Actions: Bristol-Myers, Broadcom, Jabil Circuit and More 8:23 a.m. Nov. 13, 2014 - TheStreet.com
Morgan Stanley Downgrades Bristol-Myers On Valuation 8:01 a.m. Nov. 13, 2014 - benzinga.com
One Reason Bristol-Myers Squibb (BMY) Stock Is Down Today 8:00 a.m. Nov. 13, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: Applied Materials, Broadcom, Cisco, Genworth, SanDisk and More 7:31 a.m. Nov. 13, 2014 - 247WallSt.com
New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination 5:59 a.m. Nov. 13, 2014 - CNW Group
Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial 5:59 a.m. Nov. 13, 2014 - CNW Group
3 Stocks Reiterated As A Buy: MSFT, BMY, BIDU 9:59 a.m. Nov. 12, 2014 - TheStreet.com
Bristol-Myers Squibb's (BMY) CFO Charlie Banccroft on Credit Suisse Healthcare Conference - Transcript 5:43 p.m. Nov. 11, 2014 - Seeking Alpha
Loading more headlines...
Press Releases on BMY
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) 8:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial 3:45 a.m. Nov. 16, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting 8:36 a.m. Nov. 12, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Foundation Awards $2 Million in New Grantsto Help Veterans and their Families Transition from Military to Civilian Life 9:00 a.m. Nov. 10, 2014 - BusinessWire - BZX
Upcoming Conferences, Contract Award, Quarterly Financial Results, and Completion of Acquisition - Research Reports on Bristol-Myers Squibb, 3M, Colony Financial, NOV and PPG 8:40 a.m. Nov. 10, 2014 - PR Newswire - PRF
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives the LEAD Award from The US Oncology Network 10:33 a.m. Nov. 7, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors 8:35 a.m. Nov. 5, 2014 - PR Newswire - PRF
Lexicon Strengthens Clincial Operations And Commercial Readiness 4:15 p.m. Nov. 4, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference 10:00 a.m. Nov. 4, 2014 - BusinessWire - BZX
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro 8:45 a.m. Nov. 3, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis 8:31 a.m. Nov. 3, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement 1:00 p.m. Oct. 30, 2014 - BusinessWire - BZX
Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers 12:45 p.m. Oct. 30, 2014 - PR Newswire - PRF
The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs 12:00 p.m. Oct. 29, 2014 - PR Newswire - PRF
OliPass Announces a Worldwide Discovery Alliance with Bristol-Myers Squibb for PNA-based Therapeutics 8:50 a.m. Oct. 28, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy 7:03 a.m. Oct. 28, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Loading more headlines...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Northern Jet Names Veteran Matthew Harris as CEO

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Karoo Health Leaps Forward with New CCO Breton

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

TA Services Strengthens U.S.-Mexico Freight Operations

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Pushing for National Liver Cancer Awareness in 2026

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

IWP and VYRE Unveil 'The Plug' for VBNGtv Content

Bringing Capital and Content Under One Roof There's something in the air as Itibari-Waynne & Partners (IWP) team up with the VYRE Network to crank out a fresh slate of content for VYRE Business News Global (VBNGtv). This partnership ain't just another splash in the buzzy world of digital media; it's like merging Wall Street with Hollywood. IWP, prepping to go full...

Truss Financial Tackles Home Equity Closing Delays

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...